CDTI funds Inkemia project to fight type-1 hypotonic dystrophy
<p>The group hopes to develop two products in two years for this disease, which is the most common form of muscular dystrophy in adults</p>
IUCT, the knowledge division of the Inkemia IUCT Group, has gained approval from the Center for the Development of Industrial Technology (CDTI) to conduct an R&D project to develop food supplements to improve quality of life for patients with type 1 hypotonic dystrophy.
The company expects this project to net them operating revenue of €105,891 over two years, in which time the group hopes to develop two products and launch them to market. To do so, it has received a €494,158 grant from the CDTI.
The project is really a continuation of the initial research partially funded through La Fundació La Mataró de TV3, from 2011 to 2014. The consortium identified six molecules that act to combat type-1 hypotonic dystrophy and presented two international patent applications. The aim of this project now is to finish what they began and develop at least two formulations.
Type-1 hypotonic dystrophy, although a rare disease, is the most common form of muscular dystrophy in adults and is defined as a multisystem genetic neuromuscular disease. It can cause mobility, cardiovascular and digestive disorders, among others. There are currently no effective therapies for patients with this disease.